Rev. OFIL 2017, 27;4:335-340
Fecha de recepción: 03/10/2016 – Fecha de aceptación: 28/02/2017
Alonso Domínguez MT, Nájera Pérez MD, Soria Soto M, Titos Arcos JC, León Villar J, Sánchez Catalicio MM
Servicio de Farmacia. Hospital Universitario Morales Meseguer. Murcia (España)
Mª Teresa Alonso Domínguez
Servicio de Farmacia
Hospital Universitario Morales Meseguer
Avda. Marqués de los Vélez, s/n
Correo electrónico: Teresaldo87@gmail.com
Purpose: To analyze the effectiviness and safety of regorafenib in patients diagnosed with metastatic colorectal cancer in a hospital clinical practice
Material and methods: An 18 months observational retrospective study that included patients on regorafenib. The following variables were included: gender, age, ECOG (Eastern Cooperative Oncology Group) scale, initial dose and adjustments, KRAS gene (mutated or native), previous line treatment and adverse events (AEs). In terms of effectiveness: Overall survival (OS), progression-free survival (PFS), response to treatment according to RECIST (Response Evaluation Criteria in Solid Tumors), duration of therapy and reason for discontinuation.
Results: A total of 33 patients with a median of 60 years old (36-79), started the treatment; 17 (51.5%) were male and a median duration of treatment of 3.3 months (0.4-17.3). 72.7% (24) had an ECOG 0-1. 57.5% (19) had mutated K-RAS and a median of 3 (1-5) previous line treatments. 84.4% of patients began with a full dose (160 mg) and 33.3% (11) had dose adjustment. The median days of treatment was 3.3 (0.4-17.3); SLP 3.8 (0.4-17.3) and the OS was 4.6 months (0.4-11.4). 84.8% (28) of patients reported adverse events. The response was evaluated in 87.8% (29) of the patients and 72.4% (21) had disease progression (DP).
Key Words: Regorafenib, metastatic colorectal cancer, effectiveness, safety.